Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
a technology of immunotherapy and compositions, applied in the field of immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer, can solve the problems of life-threatening disease, erratic interplay, and insufficient binding of antibodies to arrest the replication of bacteria that multiply outside cells
Examples
example 1
Treatment of Septic Shock
[0205]JR is a 72-year-old white male with a history of non-Hodgkin's lymphoma having past therapy with various cytotoxic drugs, corticosteroids, as well as Rituxan®, and presenting with stable lymphoma and a past history of several infections that required prolonged antibiotic therapy. He is admitted to the emergency department after being evaluated by his general practitioner with high temperature (40.7° C.), chills, dyspnea, palpitations, agitation, some confusion, and cool extremities. Examination reveals tachycardia (>90 / min), hypotension (95 / 60 mm Hg), especially upon standing, and a reduced urine output (800 mL / d), and signs of pneumonia. Tests show a low oxygen tension and acidosis, a blood count not detecting infection, but instead neurtopenia (3,500 WBC / mL, with 10% bands), platelets of 48,000, Hg of 6 g / dL, chest x-ray reveals a generalized pneumonia, blood tests indicate reduced renal function, with abnormal serum creatinine (3 mg / dL) and BUN leve...
example 2
Therapy of Systemic Lupus Erythematosus (SLE)
[0206]S.R. is a 32-year-old African-American female diagnosed 5 years earlier with SLE, when she presented with a globerulonephritis (WHO grade 3), serositis, polyarthritis, and a vasculitic rash. She had prior therapy with corticosteroids (range of 15-60 mg per day) and hyrdoxychloroquine (200 mg / day), and at a later time also azathioprine (100 mg / day) and a course of cyclophosphamide) because of persistent disease. Over the years, she experienced flares of her SLE, presenting with polyarthritis, lethargy, skin rash, and serositis. She now presents with persistently active disease and unresponsive to conventional therapies, but is maintained on 40 mg prednisone daily. She is given humanized anti-CD22 monoclonal antibody, epratuzumab, at 400 mg i.v. over 1 hr, repeated once in each of the following two weeks. Four weeks after the third infusion, her circulating B-lymphocytes are reduced by 40% from baseline prior to therapy, but her Hg le...
example 3
Therapy of Non-Hodgkin's Lymphoma (NHL)
[0207]SL is a 66-year-old white male with a history of diffuse large-cell NHL that has relapsed after therapy with CHOP and rituximab, and is now presenting with fever, lung and mediastinal infiltrates, enlarged cervical and axillary lymph nodes, and evidence of bone marrow involvement based on aspiration and cytology. He receives 6 weekly infusions of two humanized antibodies, one against TNF-α and the other against MIF, each given on the same day sequentially, over a 3-4-hr infusion for each, at a dose of each of 450 mg. Twenty-four hours after the last infusion, his examination indicates that he has no major toxicities to the therapy, and some palpable softening of his cervical and axillary lymph nodes. At the next follow-up examination in 8 weeks, almost all of his cervical and about half of these axillary nodes have disappeared, and his chest x-ray and CT scan show evidence of about a 60% shrinkage of his pulmonary and mediastinal infiltra...
PUM
Login to View More Abstract
Description
Claims
Application Information
- IPC
- A61K38/02; A61K39/395; A61P37/00
- CPC
- A61K49/0002; A61K2039/505; A61K2039/507; C07K16/1203; C07K16/24; C07K16/241; C07K16/248; C07K16/2803
- Inventors
- GOLDENBERG, DAVID M.; HANSEN, HANS J.